Sangamo BioSciences (SGMO) PT Lowered to $1.50 at Jefferies

Jefferies analyst Maury Raycroft lowered the price target on Sangamo BioSciences (NASDAQ: SGMO) to $1.50 (from $2.00) while maintaining a Buy rating.

The analyst comments "SGMO announced financing of $23M at mkt close to extend runway to 3Q, giving the co add'l time to secure a Fabry deal w/ multiple parties involved. Co is focused on analyzing and showing top-line eGFR data in June'25 -- we think the finalized data could increase chances a deal goes through. Though SGMO's position is risky, the fact that multiple parties remain interested+engaged is encouraging."

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Stripe, Advent In Talks To Buy Paypal - WSJ
• Berkshire adds significantly to Alphabet position, starts small position in DR Horton